Dealmaking Pays Off For Allergan As Revenue Rises 124% In 2015
This article was originally published in Scrip
Executive Summary
Allergan PLC's dealmaking ways paid off in 2015 as revenue rose 124% to $15.1bn and non-GAAP earnings per share grew 78% to $13.43, thanks in large part to Actavis PLC's $66bn acquisition of Botox (onabotulinumtoxinA) maker Allergan Inc. last year and other recent transactions.
You may also be interested in...
PhRMA Uses Allergan Stage In Campaign To Keep Focus On Industry's Reputation For Innovation
PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.